CytRx Corp (CYTR) - Strategic SWOT Analysis Review

October 2019 | 40 pages | ID: CC38A35C83AFEN
GlobalData

Abstracts

CytRx Corp (CYTR) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

CytRx Corp (CytRx) is a clinical stage is a biopharmaceutical company that focuses on the discovery, development and commercialization of new therapeutics for the treatment of cancer patients. CytRx’s lead product aldoxorubicin is in the late stage of clinical development and finds application in treating relapsed soft tissue melanoma, small-cell lung cancer and other types of cancer with unmet medical needs. The company also has other pipeline products being developed through Linker Activated Drug Release technology platform. CytRx is headquartered in Los Angeles, California, the US.

CytRx Corp Key Recent Developments

May 15,2019: CytRx reports first quarter 2019 financial results
Mar 29,2019: CytRx corporation reports 2018 financial results
Feb 11,2019: CytRx highlights majority of cancer patients do not have targetable genetic mutations and are therefore candidates for chemotherapy
Dec 21,2018: CytRx announces conclusion of pre-clinical phase for its albumin binding ultra high potency LADR drug candidates and accompanying companion diagnostic
Aug 06,2018: CytRx Reports Second Quarter 2018 Financial Results

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

CytRx Corp - Key Facts
CytRx Corp - Key Employees
CytRx Corp - Key Employee Biographies
CytRx Corp - Major Products and Services
CytRx Corp - History
CytRx Corp - Company Statement
CytRx Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
CytRx Corp - Business Description
CytRx Corp - SWOT Analysis
SWOT Analysis - Overview
CytRx Corp - Strengths
CytRx Corp - Weaknesses
CytRx Corp - Opportunities
CytRx Corp - Threats
CytRx Corp - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
CytRx Corp, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

May 15, 2019: CytRx reports first quarter 2019 financial results
Mar 29, 2019: CytRx corporation reports 2018 financial results
Feb 11, 2019: CytRx highlights majority of cancer patients do not have targetable genetic mutations and are therefore candidates for chemotherapy
Dec 21, 2018: CytRx announces conclusion of pre-clinical phase for its albumin binding ultra high potency LADR drug candidates and accompanying companion diagnostic
Aug 06, 2018: CytRx Reports Second Quarter 2018 Financial Results
Jun 25, 2018: CytRx joins Russell Microcap Index
Jun 04, 2018: CytRx Launches Centurion BioPharma to Advance LADR Albumin Binding Ultra-High Potency Oncology Drug Candidates
May 08, 2018: CytRx announces First Quarter 2018 Financial Results
May 03, 2018: CytRx Names Eric L. Curtis as Its President and Chief Operating Officer
Apr 18, 2018: CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

CytRx Corp, Key Facts
CytRx Corp, Key Employees
CytRx Corp, Key Employee Biographies
CytRx Corp, Major Products and Services
CytRx Corp, History
CytRx Corp, Subsidiaries
CytRx Corp, Key Competitors
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
CytRx Corp, Recent Deals Summary

List Of Figures

LIST OF FIGURES

CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
CytRx Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Takeda Pharmaceutical Co Ltd
Sanofi
FirstString Research Inc
Seattle Genetics Inc
Pharmacyclics LLC
ZIOPHARM Oncology Inc
CTI BioPharma Corp
AstraZeneca Plc